Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current treatment of non‐alcoholic fatty liver disease
Rafael Paternostro, Michael Trauner
Journal of Internal Medicine (2022) Vol. 292, Iss. 2, pp. 190-204
Open Access | Times Cited: 174

Showing 1-25 of 174 citing articles:

MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming‐Hua Zheng, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S17-S31
Open Access | Times Cited: 239
The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
Rodrigo Zamignan Carpi, Sandra Maria Barbalho, Kátia Portero Sloan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8805-8805
Open Access | Times Cited: 88
Antioxidant Peptides from Monkfish Swim Bladders: Ameliorating NAFLD In Vitro by Suppressing Lipid Accumulation and Oxidative Stress via Regulating AMPK/Nrf2 Pathway
Ming‐Feng Wu, Qing-Hao Xi, Sheng Yan, et al.
Marine Drugs (2023) Vol. 21, Iss. 6, pp. 360-360
Open Access | Times Cited: 77
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies
Muthukumaran Jayachandran, Shen Qu
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 6, pp. 1189-1204
Closed Access | Times Cited: 31
Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography
Xiangjun Qi, Jiayun Guo, Yanlong Li, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 14
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1859-1859
Open Access | Times Cited: 13
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
Xin Ding, Xu He, Bulang Tang, et al.
Chinese Medicine (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 12
Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3694-3694
Open Access | Times Cited: 12
Semaglutide alters gut microbiota and improves NAFLD in db/db mice
Tuohua Mao, Chenxuan Zhang, Shuang Yang, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 710, pp. 149882-149882
Closed Access | Times Cited: 12
Adherence to an antioxidant diet and lifestyle is associated with reduced risk of cardiovascular disease and mortality among adults with nonalcoholic fatty liver disease: evidence from NHANES 1999–2018
Yingzi Li, Yipin Liu
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 12
Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols
Raissa Bulaty Tauil, Paula Takano Golono, Enzo Pereira de Lima, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1354-1354
Open Access | Times Cited: 12
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
Marija Branković, Marija Dukić, Tijana Gmizić, et al.
Diagnostics (2024) Vol. 14, Iss. 2, pp. 229-229
Open Access | Times Cited: 11
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
Jialan Wang, Suwen Jiang, Airong Hu, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27325-e27325
Open Access | Times Cited: 11
Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis
Sue Shea, Christos Lionis, Chris Kite, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 11
Polyphenol consumption and Nonalcoholic fatty liver disease risk in adults
Mehran Rahimlou, Ghazal Baghdadi, Ali Khodi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
Ziwei Guo, Qinjuan Wu, Pengfei Xie, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Polarity-Sensitive fluorescent probes based on triphenylamine for fluorescence lifetime imaging of lipid droplets
Qian Wang, Dongmei Li, Ze Zhang, et al.
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2025) Vol. 330, pp. 125694-125694
Closed Access | Times Cited: 1
1-phenyl-3-methyl-5-pyrazolone activates the AMPK pathway to alleviate western-diet induced metabolic dysfunction-associated steatohepatitis in mice
Xiaoning Chen, Jiaofeng Huang, Yue You, et al.
Clinical Nutrition (2025) Vol. 45, pp. 136-147
Closed Access | Times Cited: 1
Cordycepin alleviates metabolic dysfunction-associated liver disease by restoring mitochondrial homeostasis and reducing oxidative stress via Parkin-mediated mitophagy
Haiying Tian, Daojiang Yu, Teng Xie, et al.
Biochemical Pharmacology (2025) Vol. 232, pp. 116750-116750
Open Access | Times Cited: 1
Antioxidant Peptides from Miiuy Croaker Swim Bladders: Ameliorating Effect and Mechanism in NAFLD Cell Model through Regulation of Hypolipidemic and Antioxidant Capacity
Yumei Wang, Ming-Xue Ge, Suzhen Ran, et al.
Marine Drugs (2025) Vol. 23, Iss. 2, pp. 63-63
Open Access | Times Cited: 1
The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Hongsheng Li, Yanli Hou, Xin Wang, et al.
Pharmacological Research (2025) Vol. 213, pp. 107647-107647
Open Access | Times Cited: 1
METTL3 promotes the progression of non-alcoholic fatty liver disease by mediating m6A methylation of FAS
Qun-Hua Li, Jun Xiang
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
Jeysson E. Mejía-Guzmán, Ramón A. Belmont-Hernández, Norberto C. Chávez‐Tapia, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2959-2959
Open Access | Times Cited: 1
Assessing the causal relationships between human blood metabolites and the risk of NAFLD: A comprehensive mendelian randomization study
Ziwei Guo, Tingyu Zhang, Zhangjun Yun, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top